MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

WHI-P180

CAS No. : 211555-08-7

MCE 站：WHI-P180

产品活性：WHI-P180 (Janex 3)是多种激酶抑制剂；抑制 RET，KDR 和 EGFR 的IC₅₀ 值分别为5 nM，66 nM 和4 μM。

研究领域：Protein Tyrosine Kinase/RTK  |  JAK/STAT Signaling

作用靶点：RET  |  VEGFR  |  EGFR

In Vivo: WHI-P180 is also an active inhibitor of IgE-mediated mast cell responses. The elimination half-life of WHI-P180 in CD-1 mice (BALB/c mice) following i.v., i.p., or p.o. administration is less than 10 min. Systemic clearance of WHI-P180 is 6742 mL/h/kg in CD-I mice and 8188 mL/h/kg in BALB/c mice. Notably, WHI-P180, when administered in two consecutive nontoxic i.p. bolus doses of 25 mg/kg, inhibits IgE/antigen-induced vascular hyperpermeability in a well-characterized murine model of passive cutaneous anaphylaxis.

相关产品：Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  JAK/STAT Compound Library  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Differentiation Inducing Compound Library  |  Reprogramming Compound Library  |  Anti-Hepatitis C Virus Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Gefitinib  |  Trastuzumab  |  Erlotinib  |  Cetuximab  |  AG490  |  Bevacizumab  |  Sunitinib  |  Semaxinib  |  Genistein  |  AG-1478  |  SU 5402  |  PD173074  |  Pertuzumab  |  BI-4020  |  5Z-7-Oxozeaenol  |  Cediranib  |  SAR131675  |  Gandotinib  |  NSC 228155  |  GW806742X  |  Tanshinone IIA  |  PF-03814735  |  Pelitinib  |  Mubritinib  |  TX1-85-1  |  BT-13  |  Canertinib  |  Vatalanib dihydrochloride

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。